Literature DB >> 11866882

Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin.

Shi-Jie Liu1, Jian-Zhi Wang.   

Abstract

AIM: To investigate the in vivo induction of Alzheimer-like tau phosphorylation by wortmannin and the attenuation by melatonin.
METHODS: Stereotaxic technique was used for administrating wortmannin or melatonin into rat lateral ventricle. The phosphorylation of tau was analyzed by immunocytochemistry and Western blot, and ultrastructural alteration in neuronal processes was detected by electron microscopy.
RESULTS: Level of phosphorylated tau at paired helical filament-1 (PHF-1) epitope was elevated at 1 h, peaked at 6 h, and then decreased at 12 h and 24 h after injection of wortmannin 10 mumol/L. The increased tau phosphorylation at particular epitope determined at 6 h was arrested by preinjection of melatonin 10 mumol/L or 100 mumol/L for 12 h. The wortmannin-induced hyperphosphorylation of tau was mainly detected in pyramidal neuron of hippocampus, and swelled axons and depredated myelin sheaths were also seen in the same region of the brain.
CONCLUSION: Wortmannin induced in vivo Alzheimer-like hyperphosphorylation of tau at Ser396/404, and melatonin inhibited partially the pathological processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866882

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  22 in total

1.  Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5.

Authors:  Shaohui Wang; Lingqiang Zhu; Hairong Shi; Hongyun Zheng; Qing Tian; Qun Wang; Rong Liu; Jian-Zhi Wang
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

2.  Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture.

Authors:  X Li; F Lu; Q Tian; Y Yang; Q Wang; J-Z Wang
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

3.  A high-throughput screening assay for determining cellular levels of total tau protein.

Authors:  Seameen J Dehdashti; Wei Zheng; Joel R Gever; Robert Wilhelm; Dac-Trung Nguyen; Gurusingham Sittampalam; John C McKew; Christopher P Austin; Stanley B Prusiner
Journal:  Curr Alzheimer Res       Date:  2013-09       Impact factor: 3.498

Review 4.  Pharmacological Effects of Melatonin as Neuroprotectant in Rodent Model: A Review on the Current Biological Evidence.

Authors:  Hui Ying Tan; Khuen Yen Ng; Rhun Yian Koh; Soi Moi Chye
Journal:  Cell Mol Neurobiol       Date:  2019-08-21       Impact factor: 5.046

5.  Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease.

Authors:  Hongwen He; Weiguo Dong; Fang Huang
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

6.  Alzheimer's disease progression model based on integrated biomarkers and clinical measures.

Authors:  Yue Qiu; Liang Li; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2014-08-04       Impact factor: 6.150

Review 7.  The antiapoptotic activity of melatonin in neurodegenerative diseases.

Authors:  Xin Wang
Journal:  CNS Neurosci Ther       Date:  2009-10-10       Impact factor: 5.243

8.  Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

Authors:  Venkatramanujam Srinivasan; Charanjit Kaur; Seithikurippu Pandi-Perumal; Gregory M Brown; Daniel P Cardinali
Journal:  Int J Alzheimers Dis       Date:  2010-12-08

9.  Antiinflammatory activity of melatonin in central nervous system.

Authors:  Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 10.  Antioxidant therapies for Alzheimer's disease.

Authors:  Ye Feng; Xiaochuan Wang
Journal:  Oxid Med Cell Longev       Date:  2012-07-25       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.